HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report)'s share price gapped down before the market opened on Monday . The stock had previously closed at $15.69, but opened at $15.03. HUTCHMED shares last traded at $15.05, with a volume of 17,368 shares changing hands.
HUTCHMED Price Performance
The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68. The firm has a 50-day moving average price of $14.69 and a 200-day moving average price of $16.52.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio purchased a new stake in shares of HUTCHMED during the third quarter valued at approximately $35,000. Barclays PLC lifted its position in HUTCHMED by 1,483.6% during the fourth quarter. Barclays PLC now owns 2,407 shares of the company's stock valued at $35,000 after purchasing an additional 2,255 shares in the last quarter. Blue Trust Inc. grew its position in shares of HUTCHMED by 99.9% during the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company's stock worth $102,000 after purchasing an additional 3,532 shares in the last quarter. Summit Trail Advisors LLC increased its holdings in shares of HUTCHMED by 14.4% in the 4th quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock worth $189,000 after buying an additional 1,647 shares during the last quarter. Finally, OLD Mission Capital LLC purchased a new position in shares of HUTCHMED during the fourth quarter valued at approximately $230,000. Hedge funds and other institutional investors own 8.82% of the company's stock.
HUTCHMED Company Profile
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
See Also
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
